Cutaneous adverse-events in patients treated with Ibrutinib.
adverse-events
ibrutinib
skin
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
16
06
2020
revised:
30
07
2020
accepted:
08
08
2020
pubmed:
14
8
2020
medline:
15
5
2021
entrez:
14
8
2020
Statut:
ppublish
Résumé
Ibrutinib is a Burton tyrosine kinase inhibitor (BTKi) approved for the treatment of several hematologic malignancies. Analyze skin adverse events (SAE). All the patients treated with Ibrutinib featuring cutaneous adverse events were selected. Twenty five patients were retrieved with a median interval between Ibrutinib start and SAE time of onset of 120 days. Most common SAE observed involved hairs and nails. Eczematous reaction and leucocytoclastic vasculitis were also detected. One patient had a long-history Ibrutinib treatment and experienced numerous cutaneous adverse events. Infective disease such as superficial mycosis and impetigo were rarely present in our series. Despite the development of cutaneous SAE, all the patients continued their concomitant drugs without the onset of any further SAE. Our data suggest Ibrutinib-associated rash should be distinguished in early and late events and a careful dermatologic management of patients should be scheduled.
Substances chimiques
Piperidines
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14190Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107:13075-13080.
Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287-6296.
Weniger MA, Wiestner A. Molecular targeted approaches in mantle cell lymphoma. Semin Hematol. 2011;48:214-226.
Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015;372:1430-1440.
Shapiro RM, Antin JH. Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape. Expert Rev Hematol. 2020;13(5):519-532.
Kawakami Y, Kitaura J, Hata D, Yao L, Kawakami T. Functions of Bruton's tyrosine kinase in mast and B cells. J Leukoc Biol. 1999;65:286-290.
Wu H, Wang A, Zhang W, et al. Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC cells. Oncotarget. 2015;6:31313-31322.
Grabinski N, Ewald F. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Invest New Drugs. 2014;32:1096-1104.
Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717-726.
Gunderson AJ, Kaneda MM, Tsujikawa T, et al. Bruton tyrosine kinase-dependent immune cell cross-talk drives pancreas cancer. Cancer Discov. 2016;6:270-285.
Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539-2549.
Stiff A, Trikha P, Wesolowski R, et al. Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor-bearing hosts by Ibrutinib treatment. Cancer Res. 2016;76:2125-2136.
Pileri A, Agostinelli C, Sessa M, et al. Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease. Virchows Arch. 2017;470:575-582.
Iberri DJ, Kwong BY, Stevens LA, et al. Ibrutinib-associated rash: a single-Centre experience of clinicopathological features and management. Br J Haematol. 2018;180:164-166.
Jensen AB, Stausbøl-Grøn B, Riber-Hansen R, et al. Ibrutinib-associated skin toxicity: a case of maculopapular rash in a 79-year Old Caucasian male patient with relapsed Waldenstrom's Macroglobulinemia and review of the literature. Dermatol Rep. 2017;9:6976.
Mulvey JJ, Nuovo GJ, Magro CM. Cutaneous, purpuric painful nodules upon addition of Ibrutinib to RCVP therapy in a CLL patient: a distinctive reaction pattern reflecting iatrogenic Th2 to Th1 milieu reversal. Am J Dermatopathol. 2016;38:488-492.
Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in patients undergoing treatment with the Bruton tyrosine kinase inhibitor Ibrutinib for lymphoid Leukemias. JAMA Oncol. 2015;1:684-686.
Bitar C, Farooqui MZ, Valdez J, et al. Hair and nail changes during long-term therapy with Ibrutinib for chronic lymphocytic leukemia. JAMA Dermatol. 2016;152:698-701.
Ransohoff JD, Kwong BY. Cutaneous adverse events of targeted therapies for hematolymphoid malignancies. Clin Lymphoma Myeloma Leuk. 2017;17:834-851.
Singer S, Tan SY, Dewan AK, et al. Cutaneous eruptions from Ibrutinib resembling EGFR inhibitor-induced dermatologic adverse events. J Am Acad Dermatol. 2019. Online ahead of print.
Pileri A, Baraldi C, Broccoli A, et al. Cutaneous leukocytoclastic vasculitis in B-cell chronic lymphocytic leukemia patients. G Ital Dermatol Venereol. 2019;154:605-606.
Mannis G, Wu D, Dea T, Mauro T, Hsu G. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia. Am J Hematol. 2015;90:179.
El Halabi L, Cherif-Rebai K, Michot JM, et al. Ibrutinib-induced neutrophilic dermatosis. Am J Dermatopathol. 2018;40:198-200.
Yorulmaz A, Yalcin B. Paronychia and Periungual granulation as a novel side effect of Ibrutinib: a case report. Skin Append Disord. 2020;6:32-36.
Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwerkerk J, Gelderblom H. Classification and Management of Skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer. 2007;43:845-851.
Pulini S, Rupoli S, Goteri G, et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. Haematologica. 2007;92:686-689.
Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs. 2011;29:1114-1121.
Varikuti S, Singh B, Volpedo G, et al. Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells. Br J Cancer. 2020;122:1005-1013.
Peri AM, Rossio R, Tafuri F, et al. Atypical primary cutaneous Cryptococcosis during Ibrutinib therapy for chronic lymphocytic leukemia. Ann Hematol. 2019;98:2847-2849.
Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787-798.